Is IL-23 Better than IL-17 Inhibition in Psoriasis? Save
Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.
The IMMerge study was a Phase 3b, 327 patient, head-to-head, 52 week trial comparing skin outcomes in psoriasis patients randomized to receive either risankizumab (RIZ) or secukinumab (SEC).
At week 52, the PASI 100 rates were 66% for RIZ and 40% for SEC (p<0.001).
The PASI 90 at week 16 was the primary endpoint and also favored RIZ over SEC (74% vs 66%) and remained positive out to week 52 (PASI 90 87% vs 57%; p<0.001).
There were no new safety signals observed in the study and were comparable between agents.